{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T13:14:55Z","timestamp":1692537295994},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/cco.0b013e32834bb87a","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T23:56:09Z","timestamp":1317772569000},"page":"659-664","source":"Crossref","is-referenced-by-count":2,"title":["Current opinions and controversies in chronic myeloid leukaemia"],"prefix":"10.1097","volume":"23","author":[{"given":"Bhuvan","family":"Kishore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Marin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-17-20210128","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia.","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"R2-17-20210128","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused of abl and bcr genes in chronic myelogenous leukaemia.","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"key":"R3-17-20210128","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","article-title":"Editorial: Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Goldman","year":"2001","journal-title":"N Engl J Med"},{"key":"R4-17-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia.","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest"},{"key":"R5-17-20210128","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"OBrien","year":"2003","journal-title":"N Engl J Med"},{"key":"R6-17-20210128","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"R7-17-20210128","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"R8-17-20210128","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(95)92596-1","article-title":"UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Councils Working Parties for Therapeutic Trials in Adult Leukaemia.","volume":"345","author":"Allan","year":"1995","journal-title":"Lancet"},{"key":"R9-17-20210128","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1200\/JCO.2008.18.7740","article-title":"HLA-identical sibling compared with 88 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.","volume":"27","author":"Arora","year":"2009","journal-title":"J Clin Oncol"},{"key":"R10-17-20210128","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukaemia: incidence of sustained responses in an intention-to-treat analysis.","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"R11-17-20210128","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","article-title":"Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia.","volume":"92","author":"Milojkovic","year":"2010","journal-title":"Haematologica"},{"key":"R12-17-20210128","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"R13-17-20210128","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"R14-17-20210128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in good-risk chronic granulocytic leukemia.","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"R15-17-20210128","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/sj.leu.2402996","article-title":"Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.","volume":"17","author":"Marin","year":"2003","journal-title":"Leukemia"},{"key":"R17-17-20210128","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"R18-17-20210128","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia.","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R19-17-20210128","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/blood-2009-03-212969","article-title":"The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data.","volume":"114","author":"Oehler","year":"2009","journal-title":"Blood"},{"key":"R20-17-20210128","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1200\/JCO.2008.19.4076","article-title":"Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.","volume":"27","author":"Zhang","year":"2009","journal-title":"J Clin Oncol"},{"key":"R21-17-20210128","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.leukres.2009.09.026","article-title":"A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia.","volume":"34","author":"de Lavallade","year":"2010","journal-title":"Leuk Res"},{"key":"R22-17-20210128","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A gene expression signature of CD34 cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"key":"R23-17-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34 cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.","volume":"107","author":"Yong","year":"2006","journal-title":"Blood"},{"key":"R24-17-20210128","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance.","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"R25-17-20210128","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in chronic myeloid leukemia patients who achieve complete cytogenetic responses on imatinib.","volume":"24","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"R26-17-20210128","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.","volume":"26","author":"White","year":"2010","journal-title":"J Clin Oncol"},{"key":"R27-17-20210128","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.seminhematol.2010.06.003","article-title":"Current status of imatinib as frontline therapy for chronic myeloid leukemia.","volume":"47","author":"Marin","year":"2010","journal-title":"Semin Hematol"},{"key":"R28-17-20210128","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"R29-17-20210128","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"R30-17-20210128","first-page":"161","article-title":"Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy Mayo Clin P","volume":"84","author":"Jabbour","year":"2009","journal-title":"roc"},{"key":"R31-17-20210128","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","article-title":"Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.","volume":"115","author":"Alvarado","year":"2009","journal-title":"Cancer"},{"key":"R32-17-20210128","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"R33-17-20210128","first-page":"1820","article-title":"Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"1809-","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"R34-17-20210128","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term therapy.","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"R35-17-20210128","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"R36-17-20210128","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"R37-17-20210128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","article-title":"Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"R38-17-20210128","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"R39-17-20210128","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"R40-17-20210128","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"R41-17-20210128","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"R42-17-20210128","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"R43-17-20210128","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"R44-17-20210128","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","article-title":"Potent, transient inhibition of BCR-ABL with dasatinib 100mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"R45-17-20210128","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ajh.22020","article-title":"Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors.","volume":"86","author":"Breccia","year":"2011","journal-title":"Am J Hematol"},{"key":"R46-17-20210128","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1182\/blood-2010-07-293977","article-title":"Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"R47-17-20210128","doi-asserted-by":"crossref","first-page":"314a","DOI":"10.1182\/blood.V110.11.1036.1036","article-title":"Importance of early intervention with dasatinib at cytogenetic rather than hematologic resistance to imatinib abstract.","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"R48-17-20210128","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"R49-17-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"R50-17-20210128","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia.","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R51-17-20210128","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"R52-17-20210128","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients reasons for not adhering to the oral anticancer drug imatinib as prescribed.","volume":"35","author":"Eliasson","year":"2011","journal-title":"Leuk Res"},{"key":"R53-17-20210128","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.2002.20.1.214","article-title":"Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa.","volume":"20","author":"Mahon","year":"2002","journal-title":"J Clin Oncol"},{"key":"R54-17-20210128","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"R55-17-20210128","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome.","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"R56-17-20210128","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib.","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"},{"key":"R58-17-20210128","first-page":"755","article-title":"Three decades of transplantation for chronic myeloid leukemia: what have we learned B","volume":"117","author":"Pavlu","year":"2011","journal-title":"lood"},{"key":"R59-17-20210128","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1182\/blood-2010-06-291922","article-title":"Efficacy of tyrosine kinase inhibitors (TKI) as third line therapy in patients with chronic myeloid leukemia in chronic phase who have failed two prior TKI.","volume":"116","author":"Ibrahim","year":"2010","journal-title":"Blood"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e32834bb87a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:37:07Z","timestamp":1621885027000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201111000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32834bb87a","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}